Arcutis Biotherapeutics slipped about 2.5% today to US$26.43, even though the company just turned in what many biotech investors look for most. The dermatology specialist posted Q2 net product revenue of US$129.9m and reported US$15m of net income. That short term pullback sits against a bigger picture of rising revenue guidance for 2026 and a stock that had gained roughly 25% over the past three months. The rest of this earnings breakdown focuses on how durable that profit turn and growth profile might be over the next few years.

Love that Arcutis Biotherapeutics just delivered net income with strong Q2 product revenue but wondering how many other stocks combine profit with solid balance sheets? Take a look at our hand picked list of solid balance sheet and fundamentals stocks (49 results).

Q2 2026 Earnings Summary

• Q2 2026 Revenue vs Q2 2025: US$129.9m vs. US$81.5m (up about 59%)
• Q2 2026 Net Income vs Q2 2025 Net Loss: US$15.0m vs. loss of US$15.9m (swing to profit)
• Q2 2026 Basic EPS vs Q2 2025 Basic EPS: US$0.11 per share vs. loss of US$0.13 per share (return to positive earnings per share)
• Q2 2026 Trailing 12 Month Revenue vs Q2 2025 Trailing 12 Month Revenue: US$464.0m vs. US$263.5m (revenue base materially larger over the last year)

Tired of scrolling through dense earnings releases and raw figures for Arcutis Biotherapeutics? See its full financial picture with a clear visual view of the latest valuation context in the company report for Arcutis Biotherapeutics.

Arcutis bull case hinges on ZORYVE execution

Bulls argue Arcutis Biotherapeutics is becoming a cash generative dermatology platform built on durable ZORYVE demand and label expansion. Q2 gives some support to that view. Net product revenue of US$129.9m with more than 280,000 prescriptions and a swing to US$15.0m of net income shows ZORYVE can fund the business rather than rely only on external capital. Management reports ZORYVE holds just under 50% share of branded nonsteroidal topicals, with foam and new 0.05% cream contributing. The FDA approval of 0.3% cream for plaque psoriasis in children from age 2, plus the accepted sNDA for infant atopic dermatitis, are concrete milestones toward the pediatric growth narrative. Operating cash flow turned positive at US$12.6m with R&D held flat. That backs the claim that ZORYVE can support ongoing clinical work and commercial expansion, at least at current spending levels.

Bear case focuses on concentration and execution risk

The bear story centers on Arcutis being highly dependent on a single franchise while taking on higher commercial spend and payer exposure. Concentration risk is still intact. ZORYVE remains the core revenue source and there is no offsetting product at scale yet, so any setback in prescriptions, reimbursement, or class level competition would hit the P&L hard. SG&A rose to US$82.1m, up 19% year on year, as dermatology and primary care sales teams ramped. Management also plans continued DTC and virtual health investments, which pulls cash toward commercial bets ahead of the expected 2027 inflection. Gross to net is described as stable in the 50s and guided to the low 50s. That suggests payer pressure is not easing meaningfully. The Chief Commercial Officer transition adds an execution question just as primary care and pediatrics are scaling.

Check whether Arcutis Biotherapeutics' new profitability and richer P/E are backed by a balance sheet that can fund those higher SG&A and commercial bets without strain. Analyze the real runway in our financial health analysis of Arcutis Biotherapeutics stock.

Stay Ahead With Simply Wall St

If the swing to profitability and revenue profile at Arcutis Biotherapeutics has your attention, register for free with Simply Wall St and add it to a Watchlist to track price moves against fair value and watch for a setup that fits your plan. When you do own stocks, use the Portfolio Command Center to cut through market noise and focus on the key events that matter for your holdings. For a longer term view, tap into the collective insight of investors through the Community and see how others are thinking about the same risks and opportunities. Spot potential catalysts and red flags earlier so you can act with more confidence and stay a step ahead of the market.

Seeking Alternatives Beyond Arcutis Biotherapeutics

Fresh stock ideas can move fast. Breakout momentum often gets caught early while information is still under the radar for now. Do not wait for perfect clarity; act based on the information and analysis currently available.

• Scan for income workhorses that aim to keep paying while others are dropping off income lists by reviewing our curated set of 9 dividend fortresses.
• Explore long-term growth themes by checking companies tied to power demand and grid upgrades inside the focused 36 power grid technology and infrastructure stocks.
• Track future-facing hardware trends by following suppliers and producers that support quantum computing developments within the hand picked 26 quantum computing stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.